Kapitel 26: Hochdosistherapie und Stammzelltransplantation


Bence-Bruckler I, Bredeson C, Atkins H et al. (1998) A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 22: 965–969


Goldschmidt H, Hegenbart U, Haas R, Hunstein W (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m²) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17: 691–697


Jantunen E, Mahlamaki E, Nousiainen T (2000) Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (≥60 years) with non-Hodgkin's lymphoma: Comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 26: 737–741


Martino R, Romero P, Subira M et al. (1999) Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 24: 283–287


Singhal S, Powles R, Treleaven J et al. (2000) A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2–106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26: 489–496


Stewart AK, Vescio R, Schiller G et al. (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 19: 3771–3779


To LB, Haylock DN, Kimber RJ, Juttner CA (1984) High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399–410


